Boston Scientific announced a $14.5 billion cash-and-stock acquisition of Penumbra, aiming to broaden its cardiovascular and neurovascular device portfolio. Under the terms, Penumbra shareholders can elect cash or Boston Scientific stock, with roughly 73% of consideration in cash. The deal finances an $11 billion cash portion via cash on hand and new debt. The acquisition brings Penumbra’s mechanical thrombectomy and embolization devices into Boston Scientific’s global commercial footprint, positioning the combined company to address large, underserved thrombectomy and neurovascular markets. Penumbra reported robust growth—projected Q4 2025 revenue growth of about 21–22% and full-year revenue near $1.4 billion—metrics Boston Scientific cited when framing strategic fit. Investors and management framed the move as additive to topline growth and international reach; Boston Scientific highlighted the potential to scale lifesaving stroke and embolization therapies. The transaction will reshape competition in high-growth vascular segments and prompt integration work across R&D, regulatory, and commercialization teams.